Literature DB >> 12419468

Comparison of uric acid and ascorbic acid in protection against EAE.

Sergei V Spitsin1, Gwen S Scott, Tatiana Mikheeva, Anna Zborek, Rhonda B Kean, Christine M Brimer, Hilary Koprowski, D Craig Hooper.   

Abstract

Serum levels of uric acid (UA), an inhibitor of peroxynitrite- (ONOO-) related chemical reactions, became elevated approximately 30 million years ago in hominid evolution. During a similar time frame, higher mammals lost the ability to synthesize another important radical scavenger, ascorbic acid (AA), leading to the suggestion that UA may have replaced AA as an antioxidant. However, in vivo treatment with AA does not protect against the development of experimental allergic encephalomyelitis (EAE), a disease that has been associated with the activity of ONOO- and is inhibited by UA. When compared in vitro, UA and AA were found to have similar capacities to inhibit the nitrating properties of ONOO-. However UA and AA had different capacities to prevent ONOO- -mediated oxidation, especially in the presence of iron ion (Fe3+). While UA at physiological concentrations effectively blocked dihydrorhodamine-123 oxidation in the presence of Fe3+, AA did not, regardless of whether the source of ONOO- was synthetic ONOO-, SIN-1, or RAW 264.7 cells. AA also potentiated lipid peroxidation in vivo and in vitro. In conclusion, the superior protective properties of UA in EAE may be related to its ability to neutralize the oxidative properties of ONOO- in the presence of free iron ions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12419468     DOI: 10.1016/s0891-5849(02)01048-1

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  29 in total

Review 1.  Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease.

Authors:  Atsushi Enomoto; Hitoshi Endou
Journal:  Clin Exp Nephrol       Date:  2005-09       Impact factor: 2.801

Review 2.  Antioxidants in multiple sclerosis: do they have a role in therapy?

Authors:  Noel G Carlson; John W Rose
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

3.  Uric acid protects against secondary damage after spinal cord injury.

Authors:  Gwen S Scott; Salvatore Cuzzocrea; Tiziana Genovese; Hilary Koprowski; D Craig Hooper
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

Review 4.  The influence of nutritional factors on the prognosis of multiple sclerosis.

Authors:  Gloria von Geldern; Ellen M Mowry
Journal:  Nat Rev Neurol       Date:  2012-10-02       Impact factor: 42.937

5.  Loss of blood-brain barrier integrity in the spinal cord is common to experimental allergic encephalomyelitis in knockout mouse models.

Authors:  Marzena J Fabis; Gwen S Scott; Rhonda B Kean; Hilary Koprowski; D Craig Hooper
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

Review 6.  Renal urate handling: clinical relevance of recent advances.

Authors:  Naohiko Anzai; Atsushi Enomoto; Hitoshi Endou
Journal:  Curr Rheumatol Rep       Date:  2005-06       Impact factor: 4.592

7.  The treatment of multiple sclerosis with inosine.

Authors:  Clyde E Markowitz; Sergei Spitsin; Vanessa Zimmerman; Dina Jacobs; Jayaram K Udupa; D Craig Hooper; Hilary Koprowski
Journal:  J Altern Complement Med       Date:  2009-06       Impact factor: 2.579

8.  Uric acid: the oxidant-antioxidant paradox.

Authors:  Yuri Y Sautin; Richard J Johnson
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2008-06       Impact factor: 1.381

9.  Plasma urate and risk of Parkinson's disease.

Authors:  M G Weisskopf; E O'Reilly; H Chen; M A Schwarzschild; A Ascherio
Journal:  Am J Epidemiol       Date:  2007-06-20       Impact factor: 4.897

10.  Down-regulation of Myelin Gene Expression in Human Oligodendrocytes by Nitric Oxide: Implications for Demyelination in Multiple Sclerosis.

Authors:  Malabendu Jana; Kalipada Pahan
Journal:  J Clin Cell Immunol       Date:  2013-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.